Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The Programmed Death-1 (PD-1) receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Clinical antibodies blocking the interaction between PD-1 and PD-L1 restore the cytotoxic function of tumor antigen-specific T cells, yielding durable objective responses in multiple cancers. This report describes the preclinical characterization of REGN2810, a fully human hinge-stabilized IgG4(S228P) high-affinity anti–PD-1 antibody that potently blocks PD-1 interactions with PD-L1 and PD-L2. REGN2810 was characterized in a series of binding, blocking, and functional cell-based assays, and preclinical in vivo studies in mice and monkeys. In cell-based assays, REGN2810 reverses PD-1–dependent attenuation of T-cell receptor signaling in engineered T cells and enhances responses of human primary T cells. To test the in vivo activity of REGN2810, which does not cross-react with murine PD-1, knock-in mice were generated to express a hybrid protein containing the extracellular domain of human PD-1, and transmembrane and intracellular domains of mouse PD-1. In these mice, REGN2810 binds the humanized PD-1 receptor and inhibits growth of MC38 murine tumors. As REGN2810 binds to cynomolgus monkey PD-1 with high affinity, pharmacokinetic and toxicologic assessment of REGN2810 was performed in cynomolgus monkeys. High doses of REGN2810 were well tolerated, without adverse immune-related effects. These preclinical studies validate REGN2810 as a potent and promising candidate for cancer immunotherapy. Mol Cancer Ther; 16(5); 861–70. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 2×
“PD-1 receptor engagement by B7 family ligands PDL1 and PD-L2 delivers inhibitory checkpoint signals that contribute to the establishment and maintenance of peripheral immune tolerance (8-10).”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 3×
“Numerous clinical trials of anti-PD-1 monoclonal antibodies have been conducted to treat human cancers, leading to FDA approval of nivolumab (Bristol-Myers Squibb) and pembrolizumab (Merck) for several indications, as well as many ongoing trials (22-32) for these and other clinical agents.”
BackgroundSelf-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 2×
“Homozygous human PD-1 knock-in mice displayed a normal life span and no overt signs of autoimmunity for at least one year, whereas PD-1 knockout mice develop strain and tissue-specific autoimmunity (11, 12).”
BackgroundTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Cited by
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L., Lim, A. M., Chang, A. L. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805131 · Cited by 1,411
Self-citationSezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00228-2 · Cited by 789
Self-citationMigden, M. R., Khushalani, N. I., Chang, A. L. S., Lewis, K. D., Schmults, C. D., Hernandez-Aya, L., Meier, F., Schadendorf, D., Guminski, A., Hauschild, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30728-4 · Cited by 496
Self-citationGogishvili, M., Melkadze, T., Makharadze, T., Giorgadze, D., Dvorkin, M., Penkov, K., Laktionov, K., Nemsadze, G., Nechaeva, M., Rozhkova, I., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01977-y · Cited by 316
Self-citationHumanized Mice for the Study of Immuno-Oncology
De La Rochere, P., Guil-Luna, S., Decaudin, D., Azar, G., Sidhu, S. S., & Piaggio, E. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.07.001 · Cited by 291
Metadata
- Authors
- Burova, E., Hermann, A., Waite, J., Potocky, T., Lai, V., Hong, S., Liu, M., Allbritton, O., Woodruff, A., Wu, Q., D’Orvilliers, A., Garnova, E., Rafique, A., Poueymirou, W., Martin, J., Huang, T., Skokos, D., Kantrowitz, J., Popke, J., Mohrs, M., MacDonald, D., Ioffe, E., Olson, W., Lowy, I., Murphy, A., & Thurston, G.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2017-05-01
- Volume
- 16
- Issue
- 5
- Pages
- 861-870
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2593714049
- Cited by
- 114
- References
- 16
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0665
- The paper
- Burova, E., Hermann, A., Waite, J., Potocky, T., Lai, V., Hong, S., Liu, M., Allbritton, O., Woodruff, A., Wu, Q., D’Orvilliers, A., Garnova, E., Rafique, A., Poueymirou, W., Martin, J., Huang, T., Skokos, D., Kantrowitz, J., Popke, J., . . . Thurston, G. (2017). Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0665
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.